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completed by physicians indicated Getting2Goal type 2 
pumping protocol to be more efficient, time saving, and 
structured compared to their current processes. In addition, 
the primarily prescribed TDD on pump was 98.1 ± 50.0 
units and the TDD at first download was 81.4 ± 36.4 units, 
representing a 25.4 % reduction in TDD At first download. 
The percentage of all blood glucose readings below 70 mg/
dL was also very low.
Conclusions The data indicate Getting2Goal materials as 
a standard approach that is simple and efficient to initiate 
pump therapy for T2DM. At the same time, it is safe and 
a useful tool for physicians that are starting to prescribe 
pump therapy for T2DM.
Keywords CareLink · Continuous subcutaneous insulin 
infusion · Type 2 diabetes · Total daily dose
Introduction
The effective use of insulin pump therapy versus multiple 
daily injections (MDI) in insulin taking patients with type 2 
diabetes (T2DM) has been recently demonstrated in a ran-
domized controlled, interventional post-market study (OpT-
2mise) [1]. The clinical outcomes data obtained from this 
study showed that subjects on continuous subcutaneous insu-
lin infusion (CSII) had a significantly greater reduction in 
glycated hemoglobin (A1C) than subjects on multiple daily 
injections (MDI) (p ≤ 0.0001), with 55 % of subjects on 
CSII achieving an A1C < 8 versus 28 % if subjects were on 
MDI. At 6 months, there was a 20 % less insulin usage in the 
CSII group versus the MDI group [1]. The underlying moti-
vations, initial deployment, and routine use of insulin pump 
therapy are considerably different in type 1 diabetes (T1DM) 
and T2DM. Studies focusing on uncontrolled, high insulin 
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daily dosage and MDI requiring patients (i.e., insulin resist-
ant) showed better outcome for patients starting on CSII in 
comparison to their previous conventional MDI. These were 
mainly observational, randomized studies that have shed 
some light on the practice of CSII initiation in T2DM [2].
There are studies that have compared the potential benefits 
of CSII versus MDI. In one single-center longitudinal, retro-
spective observational French study, 102 poorly controlled 
T2DM patients (baseline A1C 9.3 %, 78 mmol/mol) demon-
strated a 21.5 % A1C reduction following CSII initiation [3]. 
Another French single-center study with 51 obese T2DM 
patients (A1C 9.4 %, 79 mmol/mol) demonstrated similar 
improvements in glycemic control following CSII treatment 
but with a twofold increase in TDD [4]. An observational study 
from 31 French hospitals reported a 25 % reduction in insu-
lin dose from pre-CSII baseline [5]. The number of basal rates 
per patient was also very limited in these studies [3–5]. Studies 
from the USA, India, and Israel have also demonstrated glyce-
mic control benefits with no change in the TDD [6–10].
The need for accurately configuring bolus by carbo-
hydrate content and pre-meal glucose levels adjustment 
seems to be of less importance in comparison with T1DM 
patients. The data provided by Bergenstal et al. [11] show 
that a simple dosing regimen of fixed mealtime boluses for 
T2DM patients—with no carbohydrate counting—allows 
for glycemic control comparable to that achieved with a 
more elaborate regimen. It may also be that in this patient 
population, high doses of prandial and basal insulin con-
tribute to chronic hyperinsulinemia, minimizing the ben-
efits of fine adjustments to prandial insulin boluses.
As patients with T2DM on CSII need less elaborate oper-
ation of the insulin pump, the focus of education should be 
on a simple approach to pump use with emphasis on techni-
cal issues as dexterity and autonomy assessing the presence 
of a significant cognitive or operative disability [12].
Methods
This was a physician user evaluation study. It was con-
ducted at three community based diabetes clinics (Rishon 
Lezion, Israel, Hadera, Israel, Ashkelon, Israel) and 1 at 
a hospital-based clinic (Holon, Israel). They were using 
the Getting2Goal protocol with their new T2DM patients 
who were considered for CSII therapy. These patients 
switched from MDI to Paradigm Veo™ 754 insulin pump 
(Medtronic® MiniMed®, Inc., Northridge, CA) with down-
load capabilities by CareLink® Therapy Management Soft-
ware for Diabetes (Medtronic MiniMed, Inc., Northridge, 
CA). The study collected data retrospectively and the phy-
sicians feedback on the usability of the protocol.
The Getting2Goal type 2 pumping protocol is Medtron-
ic’s stepwise approach to prescribing and managing insulin 
pump therapy for T2DM formulated by Bruce W. Bode 
MD, Ohad Cohen MD, Scott Lee MD and Yves Reznik 
MD as shown in the supplement.
The Getting2Goal concept is intended to formulate the 
current concepts and approaches to insulin pump therapy in 
patients with T2DM into a practical work flow and to aid in 
the transition from MDI to CSII therapy. The physicians and 
health care professionals for whom these worksheets and 
forms are intended for, either come from experienced cent-
ers with T1DM patients on CSII, assisting on adjustments 
to patients with T2DM, or those who are experienced with 
patients with T2DM and have less or no experience with 
pump therapy. The worksheets and forms also help to delin-
eate between the clinical responsibility in prescribing doses 
and treatment concepts (e.g., fixed versus variable meal 
doses). It also helps technical and educational issues which 
are instrumental in functional divisions and in decreasing 
the workload on physicians and health care providers.
The work sheets and forms are organized according to 
the work flow:
1. Patient selection: definition of patients, including clini-
cal criteria, suitable for CSII with the Getting2Goal 
protocol.
2. Pump initiation:
(a) Defining TDD and calculating initial pump set-
tings. Two potential methods are presented: one is 
based on previously known insulin dose and the 
other is based on patient’s weight. The method 
based on previously known insulin dose recom-
mends a 0–20 % reduction in TDD from the pre-
vious MDI regimen to CSII according to patients 
control and compliance.
(b) Defining glycemic goals (setting customized 
goals).
(c) Check list for simplified technical education—
basic pump functions (1–2 basal rate and fixed 
mealtime boluses).
3. Ongoing diabetes management: follow-up chart and 
recommendation for fine tuning of pumps parameters 
and bolus recommendations and a quick guide for 
understanding relevant information from the CareLink 
software download.
Previous use of medications (includes hypoglycaemic 
drugs) are not collected at baseline. However, during the pro-
cess of pump initiation, subjects are instructed to the use of 
insulin and other glucose-lowering medications. Subjects are 
not to take premix, intermediate, long-acting insulin injec-
tion the day of the pump start. In addition, adjustment of other 
glucose-lowering medications is to be made. These include 
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considering: (1) stop of sulfonylureas and meglitinides and (2) 
continuing metformin and incretin mimetics, insulin sensitiz-
ers and other glucose-lowering agents. Once subject reaches 
goal, the subject is to consider discontinuing medications one 
at a time to determine if BG control can be maintained or dis-
continuing TZD if patient has edema or weight gain.
Surveys were conducted in which the physicians rated 
their feedback related to acceptability of the Getting2Goal 
on a 5-point Likert scale. The perceived value and ben-
efits were evaluated by whether or not physicians agreed 
with certain statements. No attempt was made to validate 
the survey because of the study’s short duration and small 
study sample size.
The three items surveyed were:
1. Comparison of the physicians’ current processes to the 
use of the Getting2Goal type 2 pumping protocol and 
forms.
2. Perceived effect of the simple bolus protocol on 
patient’s outlook on CSII therapy.
3. Overall impression of the Getting2Goal type 2 pump-
ing protocol and forms and willingness to apply it with 
upcoming patients.
In addition, the physician’s preference of insulin dose 
and bolus plan was recorded.
Three key questions were evaluated when assessing the 
utilization of the worksheets:
1. What was the adjustment in TDD recommended by the 
physician on switching to CSII?
2. What was the difference between the dosage before 
switching and the dosage as recorded at the first 2 week 
download?
3. What was the percentage of capillary glucose meas-
urements below 70 mg/dL and over 180 mg/dL at first 
download?
IRB consent for the use retrospective data was obtained.
Fig. 1  Response to: Comparing to your current processes, the use of the Getting2Goal type 2 protocol and forms
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Results
17 patients with T2DM were switched from MDI to CSII 
treatment. Mean [±standard deviation (SD)] age was 
61.2 ± 7.7 (46–77) years, weight was 91.4 ± 21 (66–147) 
kg, BMI was 31.9 ± 7.6, A1C was 9.2 ± 1.4 % (7.2–12.3) 
and TDD on MDI was 109.1 ± 53.1 units.
Surveys completed by the physician showed that the: 
Getting2Goal type 2 pumping protocol and forms was 
acceptable to be more efficient, time saving and structured 
in comparison to their current processes (Fig. 1). Most of 
the physicians preferred the simple approach (using a fixed 
insulin dose bolus plan with 1–2 basal rates). The physi-
cians perceived that this approach made patients more 
willingly to accept recommendation of pump therapy, 
helped alleviate patient’s concern of the complexity of the 
transition, and increased patient’s information retention 
(Fig. 2).
Overall responses indicated that the physicians had a 
high level of satisfaction with the CareLink reports and 
would recommend to other physician the Getting2Goal 
program when transitioning T2DM patients into pump ther-
apy (Fig. 3).
Insulin use
Pre-pump TDD use was 109.1 ± 53.1 units. The primar-
ily prescribed TDD on pump was 98.1 ± 50.0 units and 
the TDD at first download was 81.4 ± 36.4 units, rep-
resenting a 25.4 % reduction in TDD (Fig. 4). 47 % of 
patients were planned to stay on their MDI TDD, 47 % 
of patients were prescribed a 20 % reduction of TDD and 
6 % were recommended a 30 % reduction. On the first 
download only, 20 % retained their pre-CSII TDD while 
20, 27 and 33 % of patients had reduced their pre-CSII 
TDD by 20, 30 % and more than 30 %, respectively. No 
patients had either an increase in TDD as recommended 
at the initial pump setting or at first download (which 
occurred few weeks later with physician’s pump settings 
change).
Glycemic control
At first download, the average glucose was 167.8 mg/ 
dL, average SD was 55.5 mg/dL, and both the number 
of blood glucose reading below 70 mg/dL and the per-
centage of all blood glucose readings below 70 mg/dL 
Fig. 2  Response to: With Getting2Goal simple approach (1–2 basal rate and fixed meal bolus, no carb count)
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Fig. 3  Overall assesment of the getting2goal protocol and forms
Fig. 4  TDD on (1) MDI, (2) 
primarily prescribed pump, and 
(3) at first download
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were very low (Table 1) with one patient contributing 
most of the glucose readings below 70 mg/dL (patient #1, 
Table 1).
Discussion
In this pilot survey, we attempted to assess physician’s 
acceptability of the Getting2Goal approach via the work 
sheets and forms from a response questioner, and to follow 
the implementation of the insulin plan as prescribed by the 
physician with the insulin pump download. The responses 
to the survey questionnaire were favorable as the physicians 
found the worksheets: useful and efficient in organizing the 
transition to CSII, assisting in patient management, saving 
time. The physicians were prepared to further use the work-
sheets in daily practice and to recommend the Getting2Goal 
approach to other physicians. Getting2Goal materials pro-
vide a standardized approach that is simple and efficient to 
initiating pump therapy. In addition, the CareLink software 
download is essential for T2DM as glycemic data are read-
ily available for both physicians and patients.
The goal of optimization for insulin treatment was not 
intended for this study. For the first 2–4 weeks of T2DM 
subjects switching from MDI treatment to pump treatment, 
safety is of at most concern in this study. It was designed 
to assess that non-severe hypoglycaemia events are not 
increased and no decrease in glycemic control. Subjects’ 
insulin treatment was not intensified with standardized 
titration protocol to achieve preprandial and postprandial 
glycemic target ranges. Tweaking of insulin treatment for 
subjects was modified gradually as subjects continue.
The patients profile match the patients recruited to the 
OpT2mise randomized controlled study [1], and the pro-
file of the patients in the studies that demonstrated advan-
tage of CSII in T2DM [2, 3]. These are patients with base-
line A1C above 8.5 % with high insulin dose per day and 
obesity.
Insulin dose were either unchanged or reduced by 20 % 
on initiation of CSII, while the doses at the first down-
load, 2–4 weeks after CSII initiation, further decrease in 
TDD was noted, with only 20 % of the patients remain-
ing on their pre-CSII doses. The reduction in insulin dose 
was associated with an average capillary blood glucose of 
167.8 mg/dL, which is lower than the glucose equivalent of 
the baseline A1C of 9.2 % (220 mg/dL [13] with few meas-
urements below 70 mg/dL). Although this cannot be used 
as any measure of efficacy, it does reveal that the use of 
Table 1  Insulin and glucose data at first download
Data were not downloaded
a Subject was lost to follow-up 
First download data
Total daily dose 
(TDD)
Basal Average BG SD # Above 180 mg/dL % Above 180 mg/dL # Below 70 mg/dL # Below 70 mg/dL
1 118 107 122 73 11 31 10 28
2 29 21 112 44 3 14 5 23
3 83 40 253 73 4 4 0 0
4 78 48 133 44 12 33 0 0
5 45 39.3 193 64 33 76 0 0
6 80 40 136 38 10 40 0 0
7 90 45 217 29
8 108 54 155 50 46 59 1 1
9 123 68 156 63 35 56 3 5
10a
11 142 74 212 71 92 84 0 0
12 38.3 20.8 33 71 0 0
13 62 31.5 229 87 13 87 0 0
14 121.9 39.3 147 39 28 54 0 0
15 36 139.4 37.1 8 42.1 0 0
16 76. 8 80 155.3 54. 8 S 57.1 0 0
17 26 26 156.7 66.2 11 57.9 2.0 18.2
Mean 83.1 48.1 167.8 55.5 23.1 51.1 1.4 5.0
SD 34.1 23.5 42.5 16.9 23.2 24 2.8 9.6
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the Getting2Goal guided initiation of CSII in these patients 
with T2DM was not associated with short-term adverse 
glycemic consequence.
This Getting2Goal was utilized in the OpT2mise 
study, a larger multi-national outcome study, which 
demonstrated solid evidence for greater A1C reduction 
with CSII when compared with MDI in type 2 diabe-
tes patients on MDI. The protocol was not evaluated by 
HCP outside of the OpT2mise study so therefore only 
usability conclusions could be drawn from participating 
HCP. The results from the OpT2mise trial suggests that 
is of importance to select patients who could most benefit 
from pump therapy. The run-in period prior to randomi-
zation, the dose adjustment schedule, and the Getting-
2Goal guide for applying such adjustments, allowed the 
identification of patients who were potential candidate 
for pump therapy.
We acknowledged several limitations of the study: the 
geographical area, small sample size, retrospective nature, 
the absence of CGM and lack of percentage of values >70 
and <180 mg/dL before starting protocol, and absence of 
an A1C value after protocol application.
These factors should be assessed in an appropriate 
study design in future studies to address if the protocol is 
an effective tool for improving glycemic control. How-
ever, the present study opens alternative options for those 
patients failing on current injection regimens, and suggests 
that pump therapy may therefore be considered a valuable 
therapeutic option in this population.
In conclusion, the use of the Getting2Goal worksheets 
are convenient and safe for use in transitioning patients 
with T2DM from MDI to insulin pump therapy and can be 
now assessed on a wider and multi-national level.
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